Novartis AGNVSNYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +15.13% | +12.38% | +15.26% | +9.00% | -1.64% |
| Gross Profit Growth | +16.91% | +15.17% | +18.71% | +8.86% | -4.31% |
| EBITDA Growth | +24.06% | +25.02% | +15.76% | +4.04% | -2.24% |
| Operating Income Growth | +36.72% | +38.24% | +21.18% | +24.10% | -0.26% |
| Net Income Growth | -66.77% | +34.15% | +24.49% | +23.17% | -14.52% |
| EPS Growth | -65.70% | +38.64% | +29.37% | +29.11% | -11.27% |
| EPS Diluted Growth | -65.69% | +38.93% | +29.56% | +28.66% | -11.35% |
| Weighted Average Shares Growth | -3.07% | -3.72% | -4.18% | -4.27% | -3.72% |
| Weighted Average Shares Diluted Growth | -2.95% | -3.75% | -4.20% | -4.29% | -3.74% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +64.63% | +60.93% | +36.70% | +4.53% | -46.25% |
| Free Cash Flow Growth | +43.02% | +93.96% | +47.24% | +4.61% | -46.35% |
| Receivables Growth | +1.07% | +5.74% | +8.21% | +10.23% | +33.16% |
| Inventory Growth | -3.21% | +1.50% | +9.74% | +8.12% | +9.54% |
| Asset Growth | -1.52% | +5.94% | +7.07% | +3.64% | +13.03% |
| Book Value per Share Growth | -2.62% | +0.44% | +4.99% | +6.91% | +8.78% |
| Debt Growth | +18.64% | +14.61% | +12.59% | -0.43% | +18.73% |
| R&D Expense Growth | +10.71% | -2.27% | +15.21% | +23.08% | -0.18% |
| SG&A Expenses Growth | +1.66% | +7.68% | +11.36% | +5.55% | -1.86% |